LAVA Therapeutics News

Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)

TipRanksMay 24 13:51

JMP Securities Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6

JMP Securities analyst Reni Benjamin maintains $LAVA Therapeutics(LVTX.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 35.5%

Futu NewsMay 23 13:31

Analysts' Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)

TipRanksMay 23 12:40

LAVA Therapeutics Narrows Losses, Grows Profit

TipRanksMay 22 04:57

LAVA Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementMay 22 04:10 · Announcements

LAVA Therapeutics (LVTX.US): The 2024 Q1 financial report achieved revenue of US$6.992 million, with a previous value of US$1,224 million and an expected value of US$7 million; earnings per share were -0.02 USD, previous value of -0.53 USD, and expected v

LAVA Therapeutics (LVTX.US): The 2024 Q1 financial report achieved revenue of US$6.992 million, with a previous value of US$1,224 million and an expected value of US$7 million; earnings per share were -0.02 USD, previous value of -0.53 USD, and expected value of -0.12 USD.

Zhitong FinanceMay 21 21:31

LAVA Therapeutics Q1 EPS $(0.02) Beats $(0.12) Estimate, Sales $6.99M Miss $7.00M Estimate

LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.12) by 83.33 percent. This is a 96.23 percent increase over losses of $(

BenzingaMay 21 19:50

Lava Therapeutics: Balance Sheet With Cash of $94.6M Supports Runway Into 2026 >LVTX

Lava Therapeutics: Balance Sheet With Cash of $94.6M Supports Runway Into 2026 >LVTX

Dow JonesMay 21 19:01

Lava Therapeutics 1Q Loss/Shr 2c >LVTX

Lava Therapeutics 1Q Loss/Shr 2c >LVTX

Dow JonesMay 21 19:00

Lava Therapeutics 1Q Loss $553,000 >LVTX

Lava Therapeutics 1Q Loss $553,000 >LVTX

Dow JonesMay 21 19:00

Press Release: LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results -- LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combinatio

Dow JonesMay 21 19:00

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

LAVA Therapeutics N.V. (NASDAQ: LVTX) today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference.

GlobeNewswireMay 7 04:05

Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)

TipRanksApr 3 17:10

Buy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong Financials

TipRanksMar 25 09:27

LAVA Therapeutics: A Strong Buy on Robust Financials and Promising Oncology Pipeline Advancements

TipRanksMar 23 01:25

LAVA Therapeutics GAAP EPS of -$0.24 Beats by $0.18

Seeking AlphaMar 22 00:17

LAVA Therapeutics Announces Progress and Stability

TipRanksMar 21 19:57

LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint

Yahoo FinanceMar 21 18:19

Strong Buy Rating for LAVA Therapeutics on Promising Clinical and Financial Outlook

TipRanksMar 21 18:18

HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target

HC Wainwright & Co. analyst Arthur He reiterates LAVA Therapeutics with a Buy and maintains $6 price target.

Analyst UpgradesMar 21 18:10